Philips’ investors can ill-afford another jolt to their nerves - FT中文网
登录×
电子邮件/用户名
密码
记住我
请输入邮箱和密码进行绑定操作:
请输入手机号码,通过短信验证(目前仅支持中国大陆地区的手机号):
请您阅读我们的用户注册协议隐私权保护政策,点击下方按钮即视为您接受。
飞利浦

Philips’ investors can ill-afford another jolt to their nerves

Investors in the Dutch healthcare conglomerate had until this week been enjoying a restorative patch

Some companies, it seems, receive the benefit of the doubt even if their performance is a little ho-hum. They can, for example, highlight weak Chinese demand and get away with a mere share price ripple. Other stocks take a razor-sharp cut on every lump and bump. 

Philips is a case in point. Investors in the Dutch healthcare conglomerate, which makes everything from diagnostic machines to electric shavers, had until this week been enjoying a restorative patch. Legal woes over malfunctioning sleep apnoea machines had been resolved faster and more cheaply than feared, and sales seemed to be heading in the right direction.

But a stumble has undone much of the progress. Philips’ stock has fallen 15 per cent since it released soft third-quarter results on Monday. While Italy’s Agnelli family — who made a big investment in the stock in August 2023 through their public vehicle Exor — is still in the money, this week marks a blow for those who had more recently got behind Philips’ turnaround story.

Investors must be wondering what exactly hit them. The issues Philips highlighted at third-quarter results are hardly unheard of. An anti-corruption drive at Chinese hospitals is slowing procurement of diagnostics machines — a headwind that drove guidance downgrades at rivals Siemens Healthineers and GE Healthcare after second-quarter results, points out Lisa Clive at Bernstein. And while a double-digit fall in personal care sales in China is surprising in its magnitude, the weakness of Chinese consumer demand has been widely flagged across industries.

Meanwhile, results outside China are strong. Operating margins remain healthy despite slower than expected sales. Philips does not look expensive, either. It trades on 15 times next year’s — reduced — earnings expectations despite double-digit EPS growth through to 2026, on Barclays estimates. Siemens Healthineers trades on more than 19 times.

The best explanation for the share price reaction is that Philips is suffering from sticky negative sentiment, a malady that can afflict companies that have severely spooked the market in recent history.

Curing it requires not just solving one problem, no matter how major. It requires solving all of them. That’s something that GSK, reporting on Wednesday, will be acutely aware of. Following the resolution of the Zantac heartburn medicine legal overhang, analysts are now fretting over the strength of its vaccine sales.

Traumatised investors require a long period of peace and quiet to recover their composure. Philips cannot afford another jolt to their nerves.

[email protected]

版权声明:本文版权归FT中文网所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。

Lex专栏:亚洲将遭遇“特朗普交易”的冲击

汽车行业保护主义抬头的定价过程才刚刚开始。

马斯克对特朗普的押注得到了回报

特斯拉和X的首席执行官将成为特朗普总统身边最具影响力的政治和商业顾问之一。

巴尼耶削减养老金的计划触动了法国人的神经

法国总理的这一省钱提案遭到反对,尽管人们呼吁加强代际公平。

英国学费上涨对学生和大学财务状况的影响

专家称,这些措施不足以解决高等教育经费问题或吸引来自贫困家庭的学生。

这次美国大选对美国企业意味着什么?

大选结果将对能源、汽车和制药等领域的企业产生重大影响。

德国的商业模式失败了吗?

德国三大主要产业同时陷入低迷,经济也停滞不前。政客们终于清醒过来了吗?
设置字号×
最小
较小
默认
较大
最大
分享×